# US 2025/0164501 A1 · Biochemical assays for therapeutic proteins

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0164501 A1
- Document ID: US20250164501A1
- Status: Published application
- Kind: A1
- Application number: 18/861,979
- Filed: 2022-05-02
- Published: 2025-05-22
- Earliest claimed: 2022-05-02
- Assignees: Regeneron Pharmaceuticals, Inc.
- Applicants: Regeneron Pharmaceuticals, Inc.
- Inventors: Michael Partridge; Susan Irvin; Manoj Rajadhyaksha; Aynur Hermann
- Web page: https://patentgrep.com/patent/US20250164501A1

## CPC

- G01N 33/6854: {Immunoglobulins}
- G01N 33/5306: {Improving reaction conditions, e.g. reduction of non-specific binding, promotion of specific binding}
- G01N 33/54306: {Solid-phase reaction mechanisms}
- G01N 2333/7051: T-cell receptor (TcR)-CD3 complex
- G01N 2333/70596: Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The present invention generally pertains to methods of testing the concentration of therapeutic proteins and testing for the presence of anti-drug antibodies (ADAs) against therapeutic proteins. In particular, the present invention pertains to the use of mitigating agents against interfering competing drugs in ligand binding assays or cell-based assays for the quantification of therapeutic proteins and detection of anti-drug antibodies and neutralizing antibodies against therapeutic proteins.

## Claims

### Claim 1

A method for quantifying the concentration of a therapeutic protein in a sample, comprising:
(a) contacting said sample having a competing drug to said therapeutic protein, a target of said therapeutic protein, a detection antibody, and a mitigating agent; and
(b) measuring a binding of said therapeutic protein to said target to quantify the concentration of said therapeutic protein.

### Claim 2 (depends on 1)

The method of claim 1, wherein said therapeutic protein is selected from a group consisting of an antibody, a soluble receptor, an antibody-drug conjugate, and an enzyme.

### Claim 3 (depends on 1)

The method of claim 1, wherein said therapeutic protein is a monoclonal antibody.

### Claim 4 (depends on 5)

The method of claim 5, wherein said monoclonal antibody is selected from a group consisting of an anti-PD-1 antibody, an anti-TNF antibody, an anti-PD-L1 antibody, an anti-EGFR antibody, an anti-CD20 antibody, an anti-CD38 antibody, and an anti-LAG3 antibody.

### Claim 5 (depends on 1)

The method of claim 1, wherein said therapeutic protein is a bispecific antibody.

### Claim 6 (depends on 5)

The method of claim 5, wherein said bispecific antibody is selected from a group consisting of a CD20×CD3 antibody, a BCMA×CD3 antibody, a EGFR×CD28 antibody, and a CD38×CD28 antibody.

### Claim 7 (depends on 1)

The method of claim 1, wherein said target is an antigen, a receptor, a ligand, or an enzymatic substrate.

### Claim 8 (depends on 1)

The method of claim 1, wherein said target is a cell surface protein.

### Claim 9 (depends on 1)

The method of claim 1, wherein said target is a recombinant protein.

### Claim 10 (depends on 1)

The method of claim 1, wherein said target is immobilized to a solid support.

### Claim 11 (depends on 1)

The method of claim 1, wherein said target is an enzymatic substrate.

### Claim 12 (depends on 1)

The method of claim 1, wherein said target is CD20, CD3, BCMA, PD-1, EGFR, CD28, CD38, TNF, PD-L1, or LAG3.

### Claim 13 (depends on 1)

The method of claim 1, wherein said competing drug is a monoclonal antibody.

### Claim 14 (depends on 13)

The method of claim 13, wherein said competing drug is rituximab, pembrolizumab, nivolumab, ocrelizumab, obinutuzumab, ofatumumab, ibritumomab tiuxetan, tositumomab, ublituximab, cetuximab, daratumumab, or adalimumab.

### Claim 15 (depends on 1)

The method of claim 1, wherein said competing drug is a bispecific antibody.

### Claim 16 (depends on 1)

The method of claim 1, wherein said mitigating agent is a monoclonal antibody.

### Claim 17 (depends on 1)

The method of claim 1, comprising using two, three, four or more mitigating agents.

### Claim 18 (depends on 1)

The method of claim 1, wherein said detection antibody is an anti-human IgG4 monoclonal antibody.

### Claim 19 (depends on 1)

The method of claim 1, wherein a binding of said therapeutic protein to said target is measured by quantifying signal directly or indirectly produced from said detection antibody.

### Claim 20 (depends on 19)

The method of claim 19, wherein said signal comprises fluorescence, chemiluminescence, electrochemiluminescence, or radioactivity.

### Claim 21 (depends on 19)

The method of claim 19, wherein said detection antibody comprises an affinity tag, wherein said affinity tag binds an enzyme.

### Claim 22 (depends on 21)

The method of claim 21, wherein said affinity tag comprises biotin, avidin, streptavidin or neutravidin.

### Claim 23 (depends on 21)

The method of claim 21, wherein said enzyme comprises horseradish peroxidase.

### Claim 24 (depends on 19)

The method of claim 19, wherein said detection antibody is bound by a secondary antibody, wherein said secondary antibody directly or indirectly produces a measurable signal.

### Claim 25 (depends on 1)

The method of claim 1, further comprising a pre-treatment step of contacting said sample to said mitigating agent prior to contacting said sample to said therapeutic protein or said target.

### Claim 26

A kit, comprising:
(a) a therapeutic protein;
(b) a target of said therapeutic protein;
(c) a detection antibody;
(d) a competing drug; and
(e) a mitigating agent.

### Claim 27 (depends on 26)

The kit of claim 26, wherein said therapeutic protein is cemiplimab.

### Claim 28 (depends on 26)

The kit of claim 26, wherein said target is immobilized to a solid support.

### Claim 29 (depends on 26)

The kit of claim 26, wherein said competing drug is pembrolizumab or nivolumab.

### Claim 30 (depends on 26)

The kit of claim 26, wherein said mitigating agent is a monoclonal antibody.

### Claim 31 (depends on 26)

The kit of claim 26, wherein said detection antibody is an anti-human IgG4 monoclonal antibody.
